401843-91-2

Upstream product

• 312638-87-2 4-cyclohexyl-4-hydroxymethylpiperidine-1-carboxylic acid tert-butyl ester 
• 363192-33-0 4-cyclohexyl-4-[(2-hydroxy-1,1-dimethyl-ethylamino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 363192-22-7 4-cyclohexyl-4-formyl-piperidine-1-carboxylic acid tert-butyl ester 
• 57292-44-1 N-Boc-D-(4-Cl)Phe-OH 
• 363192-34-1 1-BOC-4-cyclohexyl-4-[(4,4-dimethyloxazolidin-2-one-3-yl)methyl]piperidine 

Downstream Products

• 401843-92-3 C₂₆H₃₈ClN₃O₃*ClH 
• 746598-41-4 3-{1-[(R)-2-Amino-3-(4-chloro-phenyl)-propionyl]-4-cyclohexyl-piperidin-4-ylmethyl}-4,4-dimethyl-oxazolidin-2-one 

Relevant academic research and scientific papers

Optimization of a privileged structure leading to potent and selective human melanocortin subtype-4 receptor ligands

Design and synthesis of potent MC4 selective agonists based on cyclohexylpiperidine derived cyclic urea, oxazolidinones, and sulfonamide based privileged structures are disclosed.

SUBSTITUTED PIPERIDINES AS MELANOCORTIN RECEPTOR AGONISTS

Certain novel 4-substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.